New hope for liver cancer patients Who've run out of options
NCT ID NCT07300488
Summary
This study is testing whether a new drug called pracytarabine works better than the existing drug regorafenib for people with advanced liver cancer that has stopped responding to standard treatments. It will involve 60 adults whose cancer has continued to grow despite previous therapies. The main goal is to see if pracytarabine helps patients live longer compared to the current treatment option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, 211100, China
Conditions
Explore the condition pages connected to this study.